ASSOCIATION OF ABC POLYMORPHISM WITH ANTIEMETIC EFFICACY IN CANCER PATIENTS TREATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY

被引：0

作者：

Tsuji, Daiki ^{[1
]}

Kim, Yong-Il ^{[2
]}

Daimon, Takashi ^{[3
]}

Makuta, Ryo ^{[1
]}

Homma, Chiho ^{[2
]}

Nakamichi, Hidenori ^{[4
]}

Yamamoto, Keisuke ^{[4
]}

Hayashi, Hideki ^{[1
]}

Inoue, Kazuyuki ^{[1
]}

Itoh, Kunihiko ^{[1
]}

机构：

[1] Univ Shizuoka, Dept Clin Pharmacol & Genet, Shizuoka 4228526, Japan

[2] Seirei Hamamatsu Gen Hosp, Dept Med Oncol, Hamamatsu, Shizuoka, Japan

[3] Hyogo Coll Med, Dept Biostat, Nishinomiya, Hyogo, Japan

[4] Seirei Hamamatsu Gen Hosp, Dept Pharm, Hamamatsu, Shizuoka, Japan

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1-26-1

引用

页数：1

共 50 条

[31] Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy
Petru E.
Andel J.
Angleitner-Boubenizek L.
Steger G.
Bernhart M.
Busch K.
Gehmacher O.
Hernler T.
Kastner U.
Lanz-Veit A.
Pluschnigg U.
Polachova J.
Rohde M.
Schiller L.
Schramböck R.
Stangl W.
Thödtmann R.
Zabernigg A.
Wiener Medizinische Wochenschrift, 2008, 158 (5-6) : 169 - 173
[32] A COMPARISON OF THE ANTIEMETIC EFFICACY AND SAFETY OF INTRAMUSCULAR AND INTRAVENOUS FORMULATIONS OF GRANISETRON IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY
CONTU, A
OLMEO, N
PIRO, S
SABBATINI, R
DEPENNI, R
SILINGARDI, V
ZANIBONI, A
MERIGGI, F
DONATI, D
MAESTRI, A
TATEO, S
CARPI, A
CAMPORA, E
CORIA, B
RIVA, E
BARBIERI, P
ANTI-CANCER DRUGS, 1995, 6 (05) : 652 - 656
[33] Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
Wenzell, Candice M.
Berger, Michael J.
Blazer, Marlo A.
Crawford, Brooke S.
Griffith, Niesha L.
Wesolowski, Robert
Lustberg, Maryam B.
Phillips, Gary S.
Ramaswamy, Bhuvaneswari
Mrozek, Ewa
Flynn, Joseph M.
Shapiro, Charles L.
Layman, Rachel M.
SUPPORTIVE CARE IN CANCER, 2013, 21 (10) : 2845 - 2851
[34] Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
Candice M. Wenzell
Michael J. Berger
Marlo A. Blazer
Brooke S. Crawford
Niesha L. Griffith
Robert Wesolowski
Maryam B. Lustberg
Gary S. Phillips
Bhuvaneswari Ramaswamy
Ewa Mrozek
Joseph M. Flynn
Charles L. Shapiro
Rachel M. Layman
Supportive Care in Cancer, 2013, 21 : 2845 - 2851
[35] IMPACT OF 5-HT3 RECEPTOR ANTAGONIST SELECTION WITHIN TRIPLE ANTIEMETIC REGIMENS ON THE RISK OF UNCONTROLLED CHEMOTHERAPY-INDUCED NAUSEA IN PATIENTS WITH CANCER TREATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY
Schwartzberg, L.
Jackson, J.
Jain, G.
Balu, S.
VALUE IN HEALTH, 2011, 14 (07) : A434 - A434
[36] A PILOT STUDY COMPARING THE ADDITION OF OLANZAPINE OR APREPITANT IN AN ANTIEMETIC REGIMEN FOR HIGHLY EMETOGENIC CHEMOTHERAPY
Long, Catherine
Knoderer, Holly
Mueller, Emily
PEDIATRIC BLOOD & CANCER, 2015, 62 : 104 - 104
[37] IMPROVING ANTIEMETIC GUIDELINE ADHERENCE FOR INPATIENT ADULTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC).
Mellin, Corrine
Lexa, Mallory
Bryant, Ashley
Mason, Susan
Mayer, Deborah
ONCOLOGY NURSING FORUM, 2017, 44 (02)
[38] Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy
Friend, Amanda Jane
Phillips, Bob
ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2022, 107 (04): : 312 - 312
[39] Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy
Friend, Amanda Jane
Phillips, Bob
ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2021,
[40] Antiemetic Guidelines Using education to improve adherence and reduce incidence of CINV in patients receiving highly emetogenic chemotherapy
Mellin, Corrine
Lexa, Mallory
Bryant, Ashley Leak
Mason, Susie
Mayer, Deborah K.
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (03) : 297 - 303

← 1 2 3 4 5 →